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ABSTRACT 
 
 
  
 In this project, the growing science of transgenic animals and the effects it has on society 
are discussed.   Chapter one examines how the transgenic animal is created.  The second chapter 
explores the wide variety of current uses for this technology. Moving from the science to the 
effects on society, chapter three tackles the ethical issues that arise when building these animals, 
and the last chapter presents the legal controversies over animal patenting design and 
methodologies.  The conclusion, based on the performed research, offers the authors viewpoints 
on how transgenic technologies should continue. 
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PROJECT OBJECTIVES 
 
 
 The general purpose of this project was to develop a better understanding of how and 
why transgenic animals are created, and to discuss what this means for civilization.  The scope of 
the first chapter endeavors to explain how these animals are created, offering a brief history of 
the development of genetically modified organisms. Chapter two's purpose is to clarify why  
transgenic animals are created and how they are used.  The third chapter delves into the moral 
and ethical dilemmas that arise from the development of each category of transgenic animals.  
The last chapter chronicles how the United States government has developed guidelines and laws 
around this burgeoning technology.  The authors, with respect to the research performed, present 
a conclusion on the topic. 
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Chapter-1:  Transgenic Technology 
William Decker 
 
 
 Civilization is the mark of humanity‟s ability to morph the world in which they live. And 
nowhere is that more brilliant than a long tradition of taming the wild.  Through acts of selective 
breeding we have domesticated the horse, shaped the wolf into a Labrador, and increased the size 
of the kernels on a corn cob.  This change of plants and animals to benefit mankind has always 
been a slow crawl, and has been limited to changes within the same species by reproduction, 
until the discovery of DNA and of its manipulation by recombinant DNA technology.   Thus, we 
gained the ability to identify a specific gene within a DNA molecule that dictates a specific 
characteristic, excise it, and insert it into the DNA of another species for the purpose of giving an 
animal a whole new trait not possible by traditional breeding.  This transgenic technology can 
create a goat producing a human drug to save lives, or can create a pig whose organs are histo-
compatible with humans for patients awaiting organ transplants.  The purpose of this chapter is 
to discuss this transgenic technology, briefly explaining how it is done, as a prelude to 
subsequent chapters on whether it should be done. 
 
Traditional Methods of Genetically Modifying Organisms 
 Modifying the genetic makeup of crops is nothing new to humanity; we have been doing 
it for thousands of years through the process of selective breeding.  Corn was not always the 
large fast growing crop that it is today; it was once a wild grass native to what is now southern 
Mexico (Prindle, 2011).  Known as Teosnite, the ancestor to modern day maize has small nut-
like kernels on small feathery cods spread over the plant.  Over several thousand years, this plant 
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was bred to change into a farming staple in the Americas.  Although the Native Americans could 
not have described what was happening to the corn, as the characteristics of one strain controlled 
by its DNA was blended with the characteristics of another strain in a nearby location containing 
its own DNA.  The corn was slowly changing to grow larger kernels.  We now know that a gene 
on the first chromosome causes the ears of corn to be larger with fewer of them (Koshland, 
2011).  But all they did was select the crops which produced the largest cobs to plant the 
following year.  This kind of selective breeding is slow, happens over generations within a 
species, and is almost exclusively done with artificial pressure applied by humans.   
On the other hand, some domestication events may be a reaction to new niches created by 
people; the domestic dog and the wild wolf have almost identical DNAs but an enormous variety 
of visible differences (phenotypes) as bred by man (Prindle, 2011).  Or another method of 
genetically modifying life for pre 20th century farmers was hybridization; for example the mule 
is a cross between a male donkey and a female horse, created by reproduction between close 
species.  In the 19th century, an emergence of biological studies would bring the scientific 
method to describe how life worked. 
 
Controlling an Organism’s Characteristics:  Genes 
 Three major biological discoveries of the 19th century helped us understand what 
controls an organism‟s characteristics:  1) methods of inheritance by Gregory Mendel, 2) the 
concept of evolution by Charles Darwin, and 3) the cell theory by several Biologists.  In the 
1850s, the Monk Gregor Mendel began a series of tests to see if it was possible to generate new 
variants of peas (Maloney, 1996).  Up until these experiments, the leading theory on how 
breeding worked was one of blending, in which the parent's features would blend together 
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evenly.  What Mendel discovered was the idea of recessive genes, where although two parents 
may not exhibit a particular trait one of their children may exhibit a new trait even though it 
hasn't been seen in generations.  His experiment used two different types of common peas, one 
with smooth seeds and the other with wrinkled ones.  Under controlled conditions, he bred them 
making careful notes of the offspring produced and their numbers.  According to the “blending” 
theory, his cross would have produced a seed somewhere in-between smooth and wrinkled, but 
instead he got two distinct groups, wrinkled and smooth.  As it turns out, the gene encoding 
smoothness is dominant.  Thus, so long as one of the two genes present in the offspring (one 
from each parent) is smooth, the offspring will look smooth.  But this appearance can be 
obtained from either having two smoothness genes (homozygous) or from one smoothness gene 
and one wrinkled gene (heterozygous).  So the results of Mendel‟s crosses depended on whether 
the parental plants were homozygous, heterozygous, or a combination.  Because each parent only 
gives one of the copies to its offspring at random, it is possible for two parents who had smooth 
seeds (but were heterozygous so each also carries a recessive wrinkled gene) to produce an 
offspring with wrinkled seeds.  Although Mendel's work was never widely believed in his time, 
it explained the concept of inheritance, and in hindsight helped explain Darwin's On the Origin 
of Species.  
Darwin's work, published in 1859, set out to explain the vast number of different 
biological species, eventually postulating a selection and adaptation process involving fitness. 
With respect to Cell Theory, the discovery of cells arose from the development of the 
microscope.  Robert Hooke first used the term “cell” in 1665 to explain the pattern of cork under 
a microscope, while Leeuwenhoek observed different types of cells in the 1670‟s (Cooper and 
Hausman, 2009).  In 1824, French biologist Henri Milne-Edwards articulated the idea that 
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animal tissues where comprised of an array of globules (Robinson, 2007).  Over a decade later in 
1838, Matthias Schleiden and Theodor Schwann informally proposed their Cell Theory stating 
that all organisms are composed of cells, and it was formally published one year later in 1839 by 
Schwann (with no reference to his earlier collaborator Schleiden).   In his 1839 On Animal and 
Plant Cells, Schwann outlined the three main tenants of Cell Theory (Rhoads, 2007).  "One, the 
cell is the unit of structure, physiology, and organization in living things. Two, the cell retains a 
dual existence as a distinct entity and a building block in the construction of organisms. Three, 
cells form by free-cell formation, similar to the formation of crystals."  We now know that 
Schwann was wrong about the generation of new cells,  it was the Prussian scientist Rudolf 
Virchow who would correct this in 1858 by saying "Omnis cellula e cellua", which means cells 
arise from other cells (Alroy, 2011).  The next major leap in Molecular biology would come with 
the discovery of the DNA structure.  
 
DNA 
  In April of 1953, a paper describing the structure of DNA by Watson and Crick was 
published (Watson and Crick, 1953).  The details of the DNA life form 'blue print' is a double 
stranded molecule held together by weak base pairs.  The chains consist of alternating 
phosphate-sugar molecules that twist to form the iconic double helix form.  The sequence of the 
DNA molecule consists of four different bases: Adenine, Thymine, Guanine, and Cytosine.   Due 
to dimensional constraints, Adenine only pairs with Thymine, and Guanine with Cytosine 
(Watson and Crick, 1953).   The DNA in the human body resides either in the nucleus or 
mitochondria.  Nuclear DNA exists in 23 pairs of chromosomes, which are higher order 
structures consisting mostly of protein and DNA.   
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Discovering What Genes Do  
 Being able to sequence DNA is one thing, but identifying what the genes do is another. 
Perhaps the most intuitive way of doing this is by over expressing the gene (knock-in) or under 
expressing it (knock-down), or by deleting the gene (knock-out) in an animal, and then assaying 
the effects.   The techniques for doing this are described below in more detail, but the idea for 
gene knock-out is to make a gene inactive by inserting essentially useless DNA into a section of 
the gene being studied.  Gene knock-in is done by inserting the gene being studied under the 
control of a strong promoter to switch it on.  The inserted material can also contain marker DNA 
to allow easy screening of transgenics.   
 
Making a Transgenic Animal:  Inserting Foreign DNA into an Organism 
Transgenic animals contain a foreign gene inserted in their genome.  This process allows 
genes that would not normally be present in an animal by reproduction to become part of the 
animal‟s characteristics.  This process is accomplished by a combination of recombinant DNA 
technology (to create the combined DNAs), reproductive biology (to create the pups), and 
molecular biology (to screen for transgenic positives). 
The gene inserted into a transgenic animal is termed the transgene.  This DNA is cleaved 
from the genome of the donor (for example a human gene encoding a protein pharmaceutical) by 
cutting the donor DNA with restriction nucleases, enzymes that cut DNA at specific sequences.  
Or it is amplified by PCR (see below).  Once the transgene has been obtained, it is cloned into a 
vector (plasmid or virus) whose purpose is to further amplify the DNA and help deliver it into 
the host cells.   
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There are two main ways in which the cloned transgene is inserted into a transgenic 
animal.  The first is by microinjecting the DNA into the pro-nucleus of a newly fertilized egg 
(Figure-1).  Egg and sperm are fertilized in vitro (IVF), and before the male and female haploid 
pro-nuclei fuse to make the zygote, the DNA is injected into a pro-nucleus using a micro-
syringe.  The embryo is usually grown to the blastocyst stage to give it vigor, and then implanted 
into the uterus of a foster mother, who delivers the pups.  This technique is the most commonly 
used, is the most reliable, and creates animals whose entire tissues are transgenic. 
 
 
 
 
 
 
 
 
The second main method for creating a transgenic animal is by manipulating embryonic 
stem (ES) cells.  In this case, IVF is performed and the embryo is grown about 5 days to the 
blastocyst stage.  The blastocyst has three main features, a ring of cells called Trophoblast, an 
inner cell mass and the blastocyst cavity (Figure-2).  At this stage, the inner cell mass contains 
ES cells.  The ES cells are isolated, and then treated with viruses containing the transgene which 
insert the DNA into the ES cells.  The cells can be screened for the presence of the transgene (see 
below) before being injected back into a blastocyst.  The injected blastocyst is inserted into the 
uterus of a foster mother, as before, etc.   During the cell injection process into the blastocyst, 
Figure-1. Microinjection of DNA Into a Pro-nucleus.  This 
photograph shows a newly fertilized egg (diagram center) 
being injected with a micropipette (right).  The zygote is held 
in place with a suction pipette (left).  (University of California, 
Irvine 2011) 
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some of the cells remaining in the embryo have not been treated with virus, so do not contain the 
transgene.  Thus, the pups born from this blastocyst will be chimeras containing a mixture of 
tissues, some of which are transgenic and some not.  To make a full transgenic animal using this 
method, the animals are bred with each other. 
 
 
 
 
 
 
 
 
 
 
Screening for Transgenic Positives 
The process of creating a transgenic animal is not an efficient process, so most of the 
pups are born without the transgene.  To determine which pups contain the new gene, they must 
be screened.  The screening is usually performed by Southern blots or by polymerase chain 
reaction (PCR).   
PCR, a technique for amplifying DNA, was invented by Kary Mullis in 1983 (Mullis et 
al., 1986).  PCR allows scientists to make copies of a specific segment of DNA (for example a 
transgene) to be amplified orders of magnitude.  The PCR reaction takes place inside a thermal 
cycler, a machine which allows for precise control of temperature over a series of cycles.  First, 
Figure-2.  The Development of a Zygote into a 
Blastocyst.  The 2-cell stage is shown in the 
upper left, through the late blastula in the lower 
right.  (Weber State University, 2011) 
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the double stranded DNA template is split into single strands by heating it up to just over 90 
degrees Celsius, this step is called denaturation, and works by breaking the already weak 
hydrogen bonds between the strand base pairs. Second, the temperature lowered to about 50 
degrees Celsius, where DNA primers attach to the single stranded DNA at sites flanking the 
transgene.  Primers are short single stranded DNA chains normally 20 to 30 base pairs long, one 
is the sense strand and the other is antisense. Once the primers have annealed to the DNA, the 
temperature of the reaction is raised to about 72 degrees Celsius, and the enzyme Taq DNA 
polymerase starts replication the DNA starting where the primers have attached.  These three 
steps of denaturation, annealing, and elongation form a cycle.  If the cycle is repeated 30-40 
times, millions of copies of the DNA target will be present in the reaction tube.  This DNA will 
form a discrete band on an electrophoresis gel, identifying which animals contained the 
transgene (Roche Molecular Diagnostics, 2011; YouTube.com, 2011).  Gel electrophoresis 
separates molecules by size.  The gel is semi-porous, and allows DNA (which is slightly 
negatively charged) to move through it slowly towards the positive anode, with the smaller 
fragments moving faster than the larger ones.  The DNA band is usually visualized by staining 
with EtBr and viewing under ultraviolet light. 
The second method used for screening transgenic positives is the Southern blot method 
(Figure-3). Named after its inventor Edwin Southern (Southern, 1975), this method starts by 
cutting the animal‟s isolated DNA with a restriction enzyme to release DNA fragments (diagram 
upper left).  These DNA fragments are then introduced into an agarose gel and separated by size 
through electrophoresis, with the smaller segments moving faster.  Next, the separated DNA 
fragments are transferred to a nylon filter (diagram upper center and right). Next, a radioactively 
labeled nucleic acid probe complementary to the transgene being screened is introduced to the 
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membrane (diagram lower center) which hybridizes to the transgene if present (green band).  The 
position of the transgene becomes visible after an x-ray film is placed over the nylon filter and 
developed (dnatube.com, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Look Into the Future 
It was once thought to be an insurmountable task to sequence the entire 3 billion bases of 
the human genome, but now this has been done several times.  It was initially projected to take 
fifteen years to complete the first human genome, but the completion arrived two years sooner 
than expected.  And due to significant advances in sequencing technology, the subsequent 
attempts took much shorter (Genomics.energy.gov, 2011).  DNA sequencing and synthetic 
technology have now advanced so far that scientists in 2010 created the first totally synthetic 
Figure-3:  Diagram of a Southern Blot for Screening Transgenic Positives.  
The animal’s DNA to be screened is cut with restriction enzymes, then the 
fragments are separated by size  using electrophoresis (upper left ).  The 
DNA fragment pattern is blotted to a membrane (upper center  and right).  
The membrane is hybridized to a single-stranded DNA probe 
complementary to the transgene (lower) to visualize the transgene DNA if 
it is present in the animal’s DNA (green band).   (Blog Images, 2011) 
 
 
http://blog-images.microscopesblog.com/uploaded_images/southern-blot-
702630.gifhttp://blog-
images.microscopesblog.com/uploaded_images/southern-blot-702630.gif 
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bacterial genome, which when transformed into another bacterial cell gave it entirely new 
properties (Venter, 2010).  Dr. Craig Venter and his team created a synthetic bacterium. The 1.08 
million base pair long synthetic DNA chain was injected into a yeast cell which had been drained 
of its own genome. The synthetic cell was able to replicate and present the expected phenotype 
(Venter, 2010).  This accomplishment implies huge potentials for what can be done in the future 
by engineering entire genomes.  As an example, the flu vaccine next year could be made using a 
synthetic cell. 
 
Chapter-1 Bibliography 
Alroy, John  (2011) Rudolf Virchow.  Accessed 7/21/2011. 
http://www.nceas.ucsb.edu/~alroy/lefa/Virchow.html 
 
Blog Images (2011) Diagram of a Southern Blot. 
http://blog-images.microscopesblog.com/uploaded_images/southern-blot-702630.gif 
 
Cooper G, and Hausman RE (2009) The Cell:  A Molecular Approach.  5th Edition, Sinauer 
Associates. 
 
DNAtube.com (2011) Southern blot. Accessed 8/9/2011. 
http://www.dnatube.com/video/1512/Southern-blot  
 
Genomics.energy.gov (2011) About the Human Genome Project. Accessed 7/22/2011. 
http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml 
 
Gill, Victoria (2010) Artificial Life Breakthrough Announced by Scientists. Accessed 8/9/2011. 
http://www.bbc.co.uk/news/10132762 
 
Koshland, Marian (2011) Improving Crops from Teosinte to Corn.  Science Museum of the 
National Academy of Sciences.  Accessed 7/19/2011.  http://www.koshland-science-
museum.org/exhibitdna/crops02.jsp 
 
Lange, Karen (2011) Wolf to Woof: The Evolution of Dogs.  National Geographic Magazine. 
Accessed 7/20/2011.  
http://ngm.nationalgeographic.com/ngm/data/2002/01/01/html/ft_20020101.1.html 
 
Maloney, Frank (1996) Gregor Johan Mendel.  Villanova University.  Accessed 7/20/2011. 
http://astro4.ast.vill.edu/mendel/gregor.htm 
 15 
 
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H (1986) Specific enzymatic 
amplification of DNA in vitro: the polymerase chain reaction.  Cold Spring Harb Symp Quant 
Biol, Pt 1: 263-273.  Accessed 7/21/2011.  
http://www.scienceisart.com/A_PCR/PCRhistory_2.html 
 
Prindle, Tara (2011) Native American History of Corn.  Accessed 7/19/2011. 
http://www.nativetech.org/cornhusk/cornhusk.html 
 
Rhoads, Dan (2007) History of Cell Biology.  Accessed 7/21/2011.  
http://bitesizebio.com/articles/history-of-cell-biology/ 
 
Robinson, Richard (2007) History of Biology: Cell Theory and Cell Structure.  Accessed 
7/21/2011.  http://www.biologyreference.com/Gr-Hi/History-of-Biology-Cell-Theory-and-Cell-
Structure.html 
 
Roche Molecular Diagnostics (2011)  How Roche PCR works.  Accessed 7/22/2011. 
http://molecular.roche.com/About/pcr/Pages/PCRProcess.aspx 
 
Sample, Ian (2010) Craig Center Creates Synthetic Life Form.  Accessed 8/9/2011. 
http://www.guardian.co.uk/science/2010/may/20/craig-venter-synthetic-life-form 
 
Southern, EM (1975) Detection of Specific Sequences Among DNA Fragments Separated by 
Gel Electrophoresis.  Journal of Molecular Biology, 98: 503-517. 
 
The Germinal Period of Development (2011) Weber State University.  Accessed 8/9/2011. 
http://departments.weber.edu/chfam/prenatal/blastocyst.html 
 
University of California, Irvine (2011)   
http://research.uci.edu/tmf/images/pronuc1800.jpg 
 
University of Michigan (2011) How Do We Sequence DNA.  Accessed 7/22/2011. 
http://seqcore.brcf.med.umich.edu/doc/educ/dnapr/sequencing.html 
 
Venter, J. Craig (2010) Creatuib a Bacterial Cell Controlled by a Chemically Synthesized 
Genome.  Accessed 8/9/2011.  http://www.sciencemag.org/content/329/5987/52.full 
 
Watson JD, and Crick FHC (1953) A Structure for Deoxyribose Nucleic Acid.  Nature, 171: 
737-738.  Accessed 7/21/2011.  http://www.exploratorium.edu/origins/coldspring/printit.html 
 
Weber State University (2011) Image of a Blastocyst. 
http://departments.weber.edu/chfam/prenatal/images/Blastocyst.gif 
 
YouTube.com (2011) PCR.  Accessed 7/22/2011.  
http://www.youtube.com/watch?v=_YgXcJ4n-kQ 
 
 16 
Chapter-2:  Transgenic Applications 
Brian Schopka 
 
In the previous chapter, we discussed the technology for creating and screening 
transgenic animals, providing a few key examples where appropriate to explain the methodology 
used.   The purpose of this chapter is to more thoroughly investigate the various types of 
transgenic animals created, separating them into functional groups and providing several 
examples within each group.  Following this discussion, key animals will be re-discussed in 
subsequent chapters on ethics and legalities. 
 
Disease Models 
Disease models are transgenic animals that have been artificially injected with a foreign 
pathogenic gene with the aim of creating a living animal model for testing vaccines and other 
treatments for diseases for that disease. Usually the diseases being tested have no current cures, 
such as AIDS, cancer, or Alzheimer‟s disease. These models give scientists hope that one day we 
can discover a cure for these terminal diseases.  
 
Oncomouse 
 Among the first transgenic animals ever produced (and the first one patented) was 
Oncomouse.  Philip Leder and his colleagues at Harvard Medical School and Dupont in the early 
1980s produced a genetically modified mouse that was highly susceptible to cancer (Stewart et 
al., 1984).  This was accomplished by modifying the promoter for the mouse c-myc oncogene to 
increase its expression to trigger the growth of tumors (Bioethics and Patent Law, 2006). More 
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specifically, mice were created that carried an otherwise normal mouse myc gene, in which 
increasingly larger portions of the myc promoter region had been replaced by a hormonally 
inducible mouse mammary tumor virus (MTV) promoter which increases expression of the 
oncogene beyond its normal levels (Stewart et al., 1984).  It was discovered that the fusion of the 
MTV-promoter/c-myc genes contributed to the over-expression of the myc oncogene in 
mammary tissue, causing the growth of mammary adenocarcinomas (mammary tumors or breast 
cancer) in female mice during pregnancy. This mouse is one of the most frequently used of all 
the transgenic animals, and has been used for years to aid our understanding of carcinogenesis 
and to help screen anti-tumor agents. 
 
AIDS Mouse 
Another famous disease model is AIDS Mouse.  AIDS Mouse was created by researchers 
in Dallas in 1988 (Namikawa et al., 1988).  HIV does not normally infect mice because their 
tissues lack surface receptors needed by the virus for entry into cells, and they lack key host 
proteins needed by the virus to replicate.  The Dallas researchers solved this problem by first 
creating a “humanized” mouse containing human fetal liver, thymus tissue (lymph nodes) and 
immune cells.  The human tissue was inserted into a mouse lacking an immune system to prevent 
immune-rejection of the tissue.  Then the mouse was infected with HIV rectally, and HIV was 
able to infect the human cells in the mouse.  The virus was able to replicate enough so the mouse 
produced antibodies against the HIV virus. After autopsy, it was determined that there was HIV 
production in the lymph nodes, spleen, other immune tissues, lungs, intestines, and reproductive 
tracts of the mouse. Since the mouse produced an immune response to the virus, other mice 
created in a similar procedure can be used to test HIV vaccine candidates (Ambrose, 2007).  
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Over 33.3 million people were estimated to be living with AIDS at the end of 2007 (Avert, 
2007), so the ability to test HIV vaccines on animals is crucial to helping save the lives of 
millions of people worldwide. 
 
Alzheimer’s Mouse 
Another breakthrough disease model is Alzheimer‟s mouse. Alzheimer‟s disease is a 
neurodegenerative disease that is the sixth leading cause of death in the United States 
(Alzheimer‟s Association, 2011).  It is linked to the deposition of a starch-like protein in the 
brain called beta-amyloid, which is highly neurotoxic.  In its genetic form, found in families who 
get the disease in their 40‟s instead of the usual 70‟s, the disease occurs when a pathogenic 
mutation arises in the gene that encodes the beta-amyloid precursor protein (APP) (Games et al., 
1995). The mutation increases the improper formation of toxic beta-amyloid from its precursor, 
causing neuro-degeneration.   
Animals do not get Alzheimer‟s (with the exception of some primates that are expensive 
to work with), so scientists (including WPI‟s Prof Adams) engineered a transgenic mouse 
containing the human APP gene in the form occurring in an early-onset pedigree in Indiana (the 
Indiana mutation) to study the nature of the disease, its effects on living animals, and to screen 
possible treatments.  After only six months, the mouse brain exhibited characteristics consistent 
to that of a person with Alzheimer‟s disease, including the deposition of beta-amyloid plaque, 
neuritic damage, and the reduction in synapse density (Games et al., 1995).  Alzheimer‟s mouse 
is an especially significant breakthrough because of the previous lack of reliable animal models 
for the disease. This transgenic animal should help speed up the development of drugs for 
treating Alzheimer‟s disease in humans (Games et al, 1995), and has already been used by Elan 
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Pharmaceuticals Inc. (South San Francisco, California) to develop a vaccine capable of removing 
the beta-amyloid toxin (Schenk et al., 1999).  Elan Pharmaceuticals is currently testing the 
vaccine in human clinical trials. 
 
Parkinson’s Fly 
Among the smallest transgenic animals ever produced is Parkinson‟s fly.  Parkinson‟s 
disease (PD) is a neurodegenerative disorder in which the substantia nigra area of the brain 
deteriorates.  That area normally secretes dopamine, so the PD brain shows diminished dopamine 
and neuromuscular defects.  Several years ago, researchers first noticed dense complexes of 
proteins, known as Lewy bodies, surrounded by a halo-like ring in neurons located deep within 
the brains of people with Parkinson‟s disease. The main protein inside these Lewy bodies is 
alpha-synuclein (Feany and Bender, 2000). To create a model for PD, scientists injected both 
normal and mutated forms of the alpha-synuclein gene into Drosophila, more commonly known 
as fruit flies. The brains exhibited many characteristics of people with Parkinson‟s disease, such 
as existence of Lewy bodies and the premature death of dopamine-producing neurons (Vogel, 
2000). Parkinson‟s fly is an important breakthrough in the study of this disease because of the 
Drosophila’s short life cycle.  Researchers can use it to quickly test their ideas about the role of 
Lewy bodies and to assess the effectiveness of drugs and other approaches to treat the disease 
(Feany and Bender, 2000). 
Transpharmers 
 Transpharming is the term used to describe the production of human pharmaceuticals in 
farm animals (Betsch, 1995). These animals are called transpharmers. Animal pharming works 
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by transferring the DNA for a protein drug into another organism for production, while placing 
the gene under control of a promoter that ensures expression of the gene in the milk or blood 
(Betsch, 1995).  If the right animal is selected, and the procedure is successfully performed, the 
animal can produce the human pharmaceutical in its milk. One advantage to using animals is that 
they are able to easily reproduce and transfer their drug-producing ability to their offspring.  
Also, the majority of the time, the drug is obtained from milk, a very convenient method of 
delivery (Betsch, 1995). Some drugs that have been delivered through animal milk have been 
tPA (Tissue Plasminogen Activator) to treat blood clots, erythropoietin for anemia, and blood 
clotting factors VIII and IX for hemophilia (Betsch, 1995). These pharmaceuticals require 
modifications to the protein drugs that only complex organisms like mammals can facilitate. 
 When the method of transpharming was first developed, scientists used mostly small 
mammals like mice and other rodents (Gordon et al., 1987).  Later, it was found that the smaller 
animals scientists were using did not produce enough milk for commercial production, so 
scientists moved to using larger animals like sheep, goats and cattle (Houbendine, 1994).  
However, this was not the easiest decision for scientists to make because the smaller rodents 
matured and produced milk much faster than larger mammals, were much cheaper to use, and 
were easier to make transgenic. 
 The first transpharmer ever produced was a mouse that produced human tPA (tissue 
plasminogen activator) (Gordon et al., 1987) which is a protein that functions as a de-clotting 
agent for treating heart attacks and strokes, potentially saving the lives of millions of people. To 
successfully produce a transpharmer mouse, scientists had to fuse the tPA gene downstream from 
the murine whey acid protein (WAP) promoter which is a protein found in mouse milk. The use 
of the WAP promoter ensured expression of the tPA in the milk.  This was a huge breakthrough 
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for science and medicine because this model could continuously and autonomously produce 
pharmaceuticals through lactation (Gordon et al., 1987). 
 As transpharming technology evolved, scientists started using larger animals for 
increased milk, and therefore protein, production.  Although these animals took longer to mature 
and were much more expensive, the benefit of obtaining more pharmaceuticals per milking 
proved the time commitment and expenses justifiable. Some examples of successful larger 
tranpharmers are sheep that produce human clotting factor IX (Clark et al., 1989), goats that 
produce antithrombin III (an anti-coagulating agent) (Genzyme Transgenics, 1999), and a bull 
named Herman (Krimpenfort et al., 1991) who fathered offspring that produced human 
lactoferrin (an anti-microbial agent) (Biotech Notes, 1994).  Each procedure fused the transgenic 
human gene with the controlling promoter of an abundant protein found in the respective 
animal‟s milk to ensure the pharmaceutical protein would only be produced in the milk and 
secreted through lactation. 
 
Xenotransplanters 
 Every day in the U.S., an average of eighteen individuals die from lack of an available 
organ for transplant (National Kidney Foundation, 2011).  Until the supply of available organs 
increases, scientists are considering using animal organs for temporary transplant to save human 
lives.  As in every transplant, doctors have to be conscious of immune-rejection of the organ. 
Rejection is basically an immune response to foreign material found on the surface of the 
transplanted organ. Animals have certain proteins or sugars on the surfaces of their cells that, if 
detected by the human immune system, will force the body to enter something called hyperacute 
rejection. If a hyper-acute rejection occurs, the body will attack the foreign cells in an effort to 
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destroy them. Because of the immune reactions that most animal cells induce in the human body, 
mostly pig and primate organs have been tested while using immunosuppressant‟s to minimize 
rejection (Kaiser 2002).  However, the use of these immunosuppressants makes the patient 
susceptible to infections. 
Xenotransplantation is any procedure that involves the transplantation, implantation, or 
infusion into a human recipient of either (a) live cells, tissues, or organs from a nonhuman 
animal source, or (b) human body fluids, cells, tissues or organs that have had ex vivo contact 
with live nonhuman animal cells, tissues or organs (U.S. Food and Drug Administration, 2009).  
Xenotransplantation is heavily driven by the fact that the human need for transplantation far 
outnumbers the amount of organs available for transplants (U.S. Food and Drug Administration, 
2009). The animals used most in xenotransplantation are baboons and pigs. Baboons are 
genetically similar to humans, but they are known to carry many viruses that affect humans, and 
they reproduce very slowly.  Pigs, however, have a strikingly similar anatomy to that of humans, 
are less viral than baboons, and reproduce in litters, making them a much better prospect for a 
human transplant. Also, there are less moral objections to using pigs for xenotransplants because 
they are already widely slaughtered for food (Williams, 1996). 
Although xenotransplants are still very much in the experimental phase, some scientists 
believe that the process will someday contribute to the saving of thousands of lives of people on 
transplant lists. Xenotransplantation could also resolve the problem of rejection by knocking out 
genes encoding surface proteins viewed as foreign by humans so the body would recognize the 
organ as its own.  Scientists have already attempted many non-transgenic xenotransplant 
procedures on human patients.  For example, six baboon kidneys were transplanted into humans 
in 1964, a baboon heart into a baby in 1984, and two baboon livers into patients in 1992, but 
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none of the patients survived. However, their deaths were not a result of organ rejection, but 
rather infections that are common to patients on immunosuppressant drugs (Williams, 1996).  
Also, in 1992, two women received pig liver transplants as a “bridge” to help them survive until 
a human liver was available. In one of the women, the pig liver was placed in an exterior bag and 
attached to the main liver arteries. The other woman had the pig liver placed alongside her 
existing diseased liver, internally. The woman with the exterior liver survived long enough to 
receive a transplant, but the woman with the interior pig liver passed away before she could 
receive hers. However, there was evidence that the pig liver had indeed functioned for her 
(Williams, 1996). 
With respect to transgenic xenotransplanters, scientists in 2002 engineered pigs to lack 
the genes for alpha-1,3-galactosyltransferase that encodes an enzyme used to add galactose on 
the surface of tissues (Lai et al., 2002).  The engineered animals showed reduced galactose on 
the surface of their livers, and decreased immune-rejection in test transplants. 
 
Transgenic Food Sources 
 Transgenic food sources are plants or animals genetically modified to increase the 
efficiency of food production for human consumption (i.e. animals with less fat, larger animals 
to produce more meat, etc.).  Animal and plant genetic hybrids created by traditional breeding 
have been produced for centuries to make superior products for consumption, but transgenic 
plants and animals are relatively new.  For plants, the Flavr Savr® tomato is perhaps the most 
famous.  It was engineered by Calgene (later acquired by Monsanto) by adding an antisense gene 
to block expression of polygalacturonase, an enzyme that normally degrades pectin resulting in 
softening (Martineau, 2001).  By interfering with its production, the fruit does not ripen until 
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manufacturers are ready to artificially ripen it with ethylene gas.  The tomato variety was 
approved by the FDA in 1994 for human consumption, but was only sold for 4 years before 
production ceased in 1997 due to lack of profitability (Martineau, 2001).   
Transgenic animals for human consumption, however, are not yet on the market, mostly 
due to ethical issues and the danger of diseases and environmental release. But this does not 
mean they are not being created (Harper et al., 2006). 
 
Superpig 
 To attempt to create a pig that grew larger, leaner, and faster, scientists decided to use 
insert growth hormone genes into pigs.  Most of the so called “superpigs” were created through 
the microinjection of a transgene for growth hormone into a fertilized porcine embryo. Scientists 
eventually tested porcine, ovine, bovine, and even rat growth hormone genes for effectiveness.  
Perhaps the most famous superpigs were made in Beltsville, Maryland, and hence were named 
the Beltsville pigs. Under the supervision of the US Department of Agriculture, scientists 
microinjected pig embryos with a transgenic growth hormone (Miller et al., 1989; Pursel et al., 
1997). The pigs showed an increase in rate of gain by fifteen percent, feed efficiency by eighteen 
percent, and carcass fat was reduced by eighty percent (Rollin, 1996). Although the positive 
results may seem beneficial to society, unfortunately the superpigs also suffered serious health 
problems, including severe arthritis, heart disease, kidney and liver problems, bulging eyes, 
thickening skin, pneumonia, and many more life-threatening side effects (Rollin, 1996). The 
pigs‟ health became so bad they had to be euthanized.  Following these landmark experiments, 
the serious health issues were deemed unethical, so scientists voluntarily placed a moratorium 
banning all growth hormone transgenic experiments in mammals.  
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Superfish 
 Unlike the story with mammals, experiments in fish are a success story so far.  Two kinds 
of Superfish have been created to date, one was engineered to help the fish survive in cold water, 
and the other is analogous to Superpig and grows faster and larger on less food.  To create the 
first type of Superfish, scientists targeted genes encoding antifreeze proteins (AFPs) produced by 
marine life that can help them survive in waters of subzero temperatures (0°C to -1.8°C).  The 
AFP genes were placed under the control of a promoter that is always switched on, allowing the 
AFPs to be continually produced and secreted into the blood.  However, the levels of AFPs are 
still not high enough to allow the fish to survive longer in cold water (Fletcher and Shears 2002), 
so more experiments have to be performed. 
The second type of Superfish was far more successful, and may become the world‟s first 
FDA-approved transgenic food.  Originally created in 1997 (Devlin et al., 1997), several 
different scientific groups created large fish, but the strain created by Aquabounty Technologies 
(2011) is closest to FDA approval.  In these fish, their natural growth hormone gene was placed 
under control of a promoter that is always switched on, so these fish do not have their growth 
hormone produced seasonally like normal Salmon, and grow much larger. The rapid growth of 
the fish could cut the cost of raising salmon for human consumption in half and quadruple the 
production.  
Although these fish may help alleviate human hunger, ethicists are worried they may 
escape from their cages and cross breed with wild type salmon.  Hundreds of thousands of 
salmon escape from fish farms each year, so there is a fear the superfish could breed with wild 
salmon or compete with them for habitat. Using a computer model, Purdue University 
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researchers found that if 60 transgenic fish escaped and were introduced to a population of 
60,000 wild fish, and if they bred with each other, the wild species would become extinct in 40 
fish generations.  Aquabounty‟s fish are sterile, but if these salmon were to escape fish farms and 
try to breed, there would still be a decrease in salmon population due to wasted eggs (Clarren, 
2003).  But because the health of the fish appears normal, of all the transgenic food sources 
superfish have the highest potential to be sold commercially. 
 
Transgenic Biological Models 
 Biological models of transgenic animals are used to teach us about the functions of 
specific proteins. Genes encoding newly discovered proteins can be overexpressed or knocked 
out to determine the effects of increased or decreased expression, respectively, on the animal.  A 
gene can be knocked out to see if the animal is dysfunctional in any normal activities. Or the 
protein can be over-expressed to enhance its effects and observe which traits are amplified. 
 
ANDi the first Transgenic Monkey 
 ANDi (backwards for “inserted DNA”) was the first transgenic primate in existence 
(Chan et al., 2001).  The goal of this experiment was to see whether a monkey could insert and 
express an injected gene.  Scientists selected a simple reporter gene encoding Green Fluorescent 
Protein (GFP), found in jellyfish, because it would be harmless to the monkey and it would be 
easy to see if the transgene had been transmitted successfully.  Primate eggs were injected with a 
virus that carried the GFP gene, and ANDi was shown to take up the GFP gene.  Although the 
gene was not expressed, and he did not glow under ultraviolet light, he did produce mRNA for 
the protein (Chan et al., 2001).  ANDi proved that transgenic primate can be created, paving the 
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way for other types of transgenic primates, perhaps to make better models than provided by 
mice. The success of this experiment is a milestone in modern science because monkeys have 
such similar DNA to humans that it is invaluable to be able to test treatments for human diseases 
on this transgenic variety. 
 
Smart Mouse 
NR2B is a protein component of the NMDA receptor in the brain that predominates when 
mammals are young and can more easily learn information.  Scientists suspect this version of the 
NMDA receptor is may have a direct role in learning and memory. To test this theory, scientists 
over-expressed the NR2B gene in mice (named “Doogie” by scientists) through their adulthood 
(Tang et al., 1999).  The mice were then tested against a control group in assays for memory and 
spatial learning. The Smart Mouse group remembered objects and environments better than the 
control group.  Overall, the Smart Mouse group scored higher on all four behavioral tests tried.  
Thus, it was determined that the NR2B gene is indeed directly linked to memory and learning 
(Harmon, 1999).  
 
Super Mouse 
 Another biological model of transgenic mouse is called Super Mouse.  Several different 
versions of Supermice have been created over the years.  The original Supermouse was the 
world‟s first “expressing” transgenic animal.  It was created in 1982 by Richard Palmiter and 
colleagues to contain a rat growth hormone gene under the control of a metallothionein promoter 
which is always on, so the growth hormone is always produced and the mice grow larger 
(Palmiter et al., 1982).  Although transgenic mice had been created a decade earlier (Jaenisch and 
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Mintz, 1974), they did not express their transgene, so Supermouse became the first expressing 
transgenic animal.  
Subsequently, other types of Supermice were created by over-expressing a gene encoding 
an enzyme called phosphoenolypyruvate carboxykinases or PEPCK-C which aids in the 
production of glucose. The muscles of these Supermice were discovered to contain ten times the 
amount of mitochondria found in normal laboratory mice. This helped them utilize fatty acids for 
energy more efficiently and produce less lactic acid.  This type of Supermouse can run twice as 
long as a regular mouse, and can also breed later in life and live longer than a control mouse.  
Although this type of experiment was successful, scientists do not see gene therapy in the future 
for athletes, as it has been dubbed unethical among the scientific community. However, this 
experiment is far from useless, as scientists will use the results from this experiment to study 
human conditions which lead to the wasting of muscles (BBC, 2007). 
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Chapter-3:  Transgenic Ethics 
William Decker 
 
 
 Now that we have discussed what transgenic animals are, described how they are 
classified, and given some specific examples, we must now ask ourselves whether we should be 
using this technology.  Is it morally acceptable to not only read the biological blue print of life, 
but to alter it for our own ends?   The purpose of this chapter is to discuss the ethics of transgenic 
animals. 
 
Framing the Ethical Argument 
 In order to answer this question, we must define what it is to be a moral agent and what 
rights are extended to such agents.  As a benchmark we could say that most human beings are 
religious, and use religion to help provide a metric by which we measure the morality of 
bioengineering.  Of course this subject is not divided into clear black and white categories, and is 
strongly framed by what ends are aimed for.  When the aim of engineering life is to combat 
virulent disease, surely the end is desirable, but perhaps the means by which it is achieved 
precludes this endeavor from the moral.  For example, when we consider the categories of 
transgenic food sources, we must also realize that we have for centuries used other animals for 
nourishment.  On the other hand xenotransplanters represent an entirely new ground to be 
explored.  And some categories likely will affect more individuals than others; perhaps the 
category of bioengineering would affect nearly every human is transgenic food sources. 
What exactly makes a human being a moral agent?  In order to gauge the morality of an 
action it must first be clear that choice and actions was made by the actor.  Hence it must be that 
the actor is capable of free will.  Most, though perhaps not all, actions are available to the actor 
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choose from; in many cases the moral actor may find themselves desiring to do one action which 
is impossible.  Keeping this in mind, we define free will as an ability to make choices, especially 
those choices that act to the detriment of oneself when there are other choices which can benefit 
(Hobbes, 1839-45).  Morality is not only the concept of one's actions in regards to oneself but in 
regards to individuals around you (Fieser, 2009).  Humans having free will, therefore can be 
moral agents shown by their capacity for empathy and sympathy.  Of course not all living things 
possess free will, animals show no signs of free will.  So a question then becomes, in the face of 
different levels of moral actors, how do we determine the rights of moral actors if not all are 
created equal. 
 Perhaps man can be placed as the most complete moral actor, capable of making moral 
choices, while at the other extreme are single cell organisms which demonstrate absolutely no 
signs of moral action, entirely at the mercy of their surroundings reacting in a mechanical way.  
The study of whether an action as moral is not just a question of whether rights are infringed 
upon, it is also question of consequences and intentions (Anscombe, 1985).  When one sets out 
to cure a disease, surely the intentions are on the correct side of moral, but even the best of 
intentions can go awry.   
 
Disease Model Ethics 
Let us examine the Alzheimer's mouse as an example of a transgenic disease model.  You 
would be hard pressed to find someone who did not think this is a horrible disease that afflicts 
almost exclusively humans.  The Alzheimer's mouse allows scientists to obtain a better 
understanding of the disease and helps us design  potential cures, such as the vaccine against 
amyloid-beta designed by Elan Pharmaceuticals that was initially designed using this mouse 
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model (Schenk et al., 1999), and subsequently is being tested in human clinical trials (Elan 
Corporation, 2011).  This however means that the mouse is forced to have portions of the 
Alzheimer's disease.   It is rare for an animal to show full symptoms of any human disease, but 
such models still allow us to test potential cures.  The Alzheimer‟s mouse line experiences no 
pain based on any standard of measurements, but does learn slower on memory tests.  So the 
animal does not appear to suffer by any measurable criteria.   So the question becomes is it 
acceptable to create an animal which is destined to be sick or partially sick.  The question 
becomes are the mice's rights infringed upon, and if so, do the rights of humans to try to cure 
diseases outweigh those of the mouse?  In the case of Alzheimer‟s mouse, since the animal does 
not appear to suffer, yet it provides a strong medical benefit for man the moral agent, the ethical 
scales appear to tilt in favor of continuing that line of experimentation. 
However, some types of disease models do suffer; HIV mouse and Oncomouse are two 
examples.  The difference between the AIDS mouse and Alzheimer's mouse is the extent of 
animal suffering.  This ethical question is similar to the tradition activities at medical schools 
where mice are injected daily with bacteria or viruses to help study infectious diseases.  These 
animals are not transgenic, but they suffer for man‟s improvement.  And if the animal suffers, is 
there a way to minimize or avoid the pain?  For example, with Oncomouse is there a way to 
avoid advanced tumor formation which can be painful, and sacrifice the mice soon after the onset 
of tumors?  And is there a way to use painkillers to minimize pain when advanced tumors must 
be studied?  If so, this could be mandated by institutional IACUC committees who oversee all 
animal research. 
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Transpharmer Ethics 
 People have been using animal milk to supplement their diets for centuries, but 
engineering animals to produce human pharmaceuticals in their milk causes new ethical issues to 
arise.  In this case, the animals do not appear to suffer at all, or even know the pharmaceutical is 
being manufactured in the milk, so the strong medical benefits of saving human lives far 
outweigh any potential objection to the treatment of the animals.  This is a case similar to 
breeding a better sheep or goat.  Once the premise of raising animals for the production of milk 
in general is considered ethical, then the only difference with transpharmers is how these new 
breeds of livestock came about.  
 
Xenotranplanter Ethics 
 Although this is a very similar situation to the previous section, the key difference is the 
termination of the animal‟s life at the end.  There is no doubt that medically there is a real 
shortage of organ donors, so hopefully Xenotranplanters can help alleviate the lack of available 
organs for transplant.  There are two major arguments against developing Xenotranplanter 
animals.  The first argument comes from individuals arguing that no harm should come to any 
animal.  Although this is a worthy goal, the lives of say a few hundred organ donor animals falls 
apart when compared to the millions of animals sacrificed for food annually.  Since most people 
still consume meat on a regular basis, it is hard to believe the majority of the public would debate 
this point.  The second objection is that unforeseen consequences will occur engineering such 
animals. Although this technology is still in its experimental stages (Williams, 1996), once the 
animals have been engineered, they would just be bred normally to produce enough organs for 
transplant.   It is worth noting that the idea of giving a patient a new pig liver is to allow the 
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person to return to society.  If xenotransplantation is found to be as safe as human-to-human 
transplants, it is hard to imagine the population having an objection to the use of 
Xenotransplanters. 
 
Food Source Ethics 
 The simple fact is that everyone needs to eat.  And there is no escaping the truth that 
there is a finite amount of space in which to produce food on the planet.  But making the case for 
genetically modified crops and livestock is not as simple as meeting the need for human 
sustenance.  Many countries have trepidations about allowing genetically modified crops and 
livestock to be produced or sold.  However, these GMOs tend to have a distinct advantage over 
the normal species such as increased disease resistance, or the ability to mature on command, 
that cannot be achieved by traditional breeding.  How different is this process to generate 
superior strains from what humans have been doing for thousands of years by selective breeding?  
 Although we don't think twice about breeding a pig to make it larger, what if we were to 
genetically alter a pig to do this on a larger scale in one generation?  How different is that really?  
When Superpig was created in Maryland in 1997,  scientists after observing the serious health 
issues placed a voluntary moratorium on 'super' mammals like the Superpig (Miller et al., 1989; 
Pursel et al., 1997).  Perhaps the difference here has nothing to do with the intentions of the people 
breeding the animals but the techniques used to create them?  However, more ethically 
interesting is the fact that scientists created a self-imposed moratorium on mammalian growth 
hormone experiments, citing the animal‟s health problems. Scientists have been using traditional 
breeding for decades with mice to create new strains for studying diseases.  The only real 
difference with transgenesis is the scale of the production and method of achieving the intention;  
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the mouse is intended to help understand, treat and possibly cure the disease, but the pig is 
intended to produce food.  
On the other hand, the eventual wide-spread use might be exactly what gives most people 
pause on the food source experiments, while the organ donor animals would have a more 
restricted use.  Or can humans simply muster more empathy for a pig than for a mouse?  One 
serious ethical concern is what happens if any of the transgenic animals escape?  There is ample 
evidence for how destructive an invasive species can be on an ecosystem if the invasive species 
is dominating.  In the case of Superfish, they have been projected to replace the native salmon in 
40 generations.  However, in the case of Aquabounty‟s Superfish, they were engineered to be 
sterile, so even if they escape they cannot pass on the transgene.   
It cannot be doubted that people need to be fed, and the quantity of food required is only 
rising; making it an imperative to discover ways of producing more food at a more cost effective 
rate.  When it comes to the starvation of a people a sort of moral relativism will arise, that 
ignores the animals suffering in order to alleviate theirs.   
Nonetheless not all countries may agree that farming GMOs is unethical.  There are 
already a number of genetically engineered crops produced and sold, but not in every country. 
Although Australia in 2003 placed a ban on GM crops (Parliament of New South Wales, 2003), 
within five years half the states lifted the ban.  However, banning the production of agricultural 
GMOs in one country does not mean that neighboring countries will follow suit, and if the 
transgenic plant or animal is not sterile, it could invade the surrounding countries.  Such a 
situation occurred in Mexico, as reported in Nature in 2001, where the production of Bt maize 
was found in surrounding areas (Quist & Chapela, 2001).   But GM livestock should be easier to 
control than plants, and if the livestock are sterile most people would have no strong objections.   
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In the end, so long as to food is safe for human consumption and the risks of 
environmental contamination is kept as a reasonable level, the author finds few objections. 
Perhaps implementing GM livestock could even reduce our over-use of antibiotics with live 
stock; it might be possible engineer livestock to not need antibiotics.  The FDA has major 
concerns with our over-use of antibiotics in livestock, and it appears to facilitate the generation 
of more antibiotic-resistant bacteria (Layton, 2010).  Perhaps in the future, engineering livestock 
to have a stronger immune system could help alleviate this problem. 
 
Further Remarks (and Synthetic Cells) 
 In the end, the author of this chapter feels there are realistically two ethical concerns over 
the generation of transgenic animals: 1) A deontological one, the objection to 'playing god'; and 
2) a utilitarian conflict based on consequentialist reasoning that there will be unforeseen and 
terrifying consequences.  Unfortunately the first objection can't easily be settled as man has been 
playing god for millennia.  Humans have been tinkering with life for as long as recorded history, 
whether it is selecting only the best to breed, or shifting around some proteins.  When we ask 
whether we are “playing god” with these technologies, the hidden connotation is that we should 
not.  Perhaps we need to ask ourselves in the face of being able to generate new synthetic forms 
of life at our whim, as was recently achieved with the world‟s first synthetic bacterium, whether 
life is more than the chemical reactions that fit so nicely into logic and reason. If it is more, then 
are we arrogant to want to improve our life situation?  Always, we must keep in mind that the 
world is constantly changing around us, and as it changes the ethnical boundaries may also shift.  
Transcendental truths are not always absolute, so finding something ethical or unethical does not 
mean that it will always be that way as new evidence rises to prominence. Because ethics deals 
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with intent, action, and consequences, that may not be immediately evident, it is a discussion that 
needs to happen continuously. 
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Chapter-4: Transgenic Legalities 
Brian Schopka 
 
 Ever since the emergence of transgenic technology, there has been a barrage of legal 
issues regarding whether life can be patented.  For years, legal battles between scientists seeking 
better research opportunities and activists attempting to maintain animal rights have caused 
serious debates in the field of transgenics. The purpose of this chapter is to discuss the 
controversial topic of animal patents. 
In the US, a patent for an invention is the grant of a property right to the inventor, issued 
by the United States Patent and Trademark Office (United States Patent and Trademark Office, 
2005).  Patents are awarded based on the definition set forth in the patent law to whoever invents 
or discovers any new and useful process, machine, manufacture, or composition of matter, or any 
new and useful improvement (Bitlaw, 2000).  However, animal rights activists and many other 
groups insist that transgenesis is causing unjustified injury and death to defenseless animals. 
They also maintain that a patent on living creatures is unethical, and that a human being should 
not devalue the life of an animal or treat them as a product or invention.  So the debate begins. 
  
Diamond v. Chakrabarty 
 The first legal case involving an attempt to patent life was Diamond v. Chakrabarty 
(1980).  In 1972, Ananda Chakrabarty, a microbiologist, engineered bacteria from the genus 
Pseudomonas to contain plasmid DNAs allowing the bacteria to degrade hydrocarbons.  So this 
bacterium is capable of breaking down multiple components of crude oil, and the traits enable 
the bacteria to be used to clean up oil spills. Seeing how unique and useful his new bacterium 
was, Chakrabarty sought a patent for his creation (Diamond vs. Chakrabarty, 1980). 
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 Based on the Patent and Trademark Office requirements for obtaining a patent, his 
invention must satisfy the three requirements of novelty, utility, and non-obviousness (Bitlaw, 
2000).  The novelty requirement appeared to be easily fulfilled since there is no naturally 
occurring organism with the traits of Chakrabarty‟s bacteria; the utility requirement was fulfilled 
because of the bacteria‟s ability to clean up oil spills; and the non-obviousness requirement was 
also fulfilled since no scientist skilled in the art of genetic engineering had previously come up 
with the idea.  However, the discovery is supposed to apply to new and useful process, machine, 
manufacture, or composition of matter, and it was not clear which category the engineered 
bacteria fell under. 
 Chakrabarty was originally denied his claim by a patent examiner on the grounds that a 
living organism was not a composition of matter and could not be patented.  Chakrabarty then 
appealed his case to the Supreme Court, and the legal battle of Diamond vs. Chakrabarty was 
born. The Supreme Court eventually found that Chakrabarty‟s bacteria met the requirements set 
forth under section 101 of the patent law granting him patents for the bacteria themselves, and 
exclusive rights for the method of producing it and a carrier material floating on water with the 
bacteria (Diamond v. Chakrabarty, 1980).  
 This was a landmark case in the battle for transgenic patents because it proved that it was 
not illegal to own a patent on life as long as it followed the requirements set forth in law. This 
case paved the way for other transgenic models to be recognized in a court of law and patented. 
The decision was confirmed by The Patent and Trademark Office several years later when it 
stated that “The Patent and Trademark Office now considers non-naturally occurring non-human 
multicellular organisms, including animals, to be patentable subject matter within the scope of 35 
U.S.C. s. 101” (Edwards, 2001).   Also, the animals must be “given a new form, quality, property 
 43 
or combination not present in the original article existing in nature in accordance with existing 
law” (Patent and Trademark Office Notice, 1987). After this revision to the patent law, the door 
was left wide open for the patent of more complex transgenic organisms. 
 
Harvard and DuPont’s Oncomouse 
 What turned out to be the cornerstone case in the patenting of transgenic animals was 
Harvard‟s Oncomouse.  Oncomouse was created at Harvard University by Philip Leder and 
Timothy Stewart and was subsidized by DuPont (Leder and Stewart, 1984). As discussed in 
Chapter-2, Oncomouse describes a series of mouse models that develop tumors as a consequence 
of containing a recombinant activated oncogene sequence (Stern, 2000).  Oncomouse was 
created by modifying the promoter for the mouse c-myc oncogene to increase its expression to 
trigger the growth of tumors. This case was not only controversial because of the detriment to the 
animal‟s health, but also because it gives ownership of a species to a corporation for the first 
time (Bioethics and Patent Law, 2006). 
 After four long years of debate and deliberation, the United States Patent Office in 1988 
granted a patent no. 4,736,866 to Harvard College claiming "a transgenic non-human mammal 
whose germ cells and somatic cells contain a recombinant activated oncogene sequence 
introduced into said mammal”.  However, this claim excluded the technology from being applied 
to humans in an effort to avoid the patenting of human life, and to discourage the almost 
inevitable tampering of the human genome (Bioethics and Patent Law, 2006). Though it was a 
difficult and tedious process, the patenting of the Harvard DuPont mouse was a great success in 
the United States.  But would the acquisition of a patent like this go as smoothly in other 
countries? 
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Oncomouse in Europe 
 The European Patent Office (EPO) considered the Oncomouse case at length and at many 
different levels.  Two key provisions of the European Patent Convention discussed in the 
Oncomouse case were Article 53(a) which excludes patents for inventions "the publication or 
exploitation of which would be contrary to ordre public or morality", and Article 53(b) which 
excludes patents on "animal varieties or essentially biological processes for the production 
of…animals" (Bioethics and Patent Law, 2006).  These patent standards would seemingly put a 
lock on the denial of the Oncomouse patent, however, the EPO decided that the exclusion on 
patenting animal varieties did not constitute a ban on patenting novel engineered animals as 
such.  It concluded that the Oncomouse was not an animal variety, and so did not fall within that 
exclusion. This conclusion reached by the EPO broke the legal barrier for the Oncomouse patent, 
so the only barrier remaining was the moral and ethics barrier (Bioethics and Patent Law, 2006). 
 In order to address the morality and ethics aspect of the case, the EPO developed a 
utilitarian test aimed to weigh the potential benefits to mankind against the suffering of the 
animal. In this case more specifically, to weigh the benefit and convenience of having the 
Oncomouse to readily test vaccines and other treatments against the suffering it would have to 
endure during its lifetime. Scientists did have a few promising attributes during this test, 
however.  One, that there were no environmental risks due to the fact that the mice would be 
living in the labs their entire lives with no fear of reproduction with wild type mice in an 
ecosystem; and two, there was no evidence in European culture that there would be public 
unease about using mice for cancer research, as mice had already been used for this type of 
research for decades.  Finally, in 2004, the EPO concluded that the potential benefit to society 
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through its ability to study cancer far outweighed the moral concerns about the suffering of the 
animal (Bioethics and Patent Law, 2006).  In 1992, the Oncomouse patent was granted European 
patent number 0,169,672 (the „Harvard Oncomouse‟ patent) and claimed the method for 
producing transgenic non-human mammals with a predisposition to developing cancer (Sharples 
and Curly, 2009).  However, this case would not turn out to be a flawless victory for scientists as 
the EPO twice restricted the patent, first in 2001 from covering all mammals to covering only 
rodents, and later in 2004 adding that mice specifically were the rodent being covered 
(Cyranoski, 2004). 
 
Oncomouse in Canada 
 With patents on higher life forms approved in the United States and Europe, scientists 
sought a similar patent in Canada.  However, things would not turn out as planned.  In its 
Canadian application, Harvard sought to protect both the process by which the oncomice were 
produced and the end product of the process, (i.e. mouse and offspring whose cells contain the 
oncogene). The process and product claims extended to all similarly altered non-human 
mammals (Ching, 2003).  The Canadian Patent Act, like that in American law, defines 
"invention" as "any new and useful art, process, machine, manufacture or composition of matter, 
or any new and useful improvement in any art, process, machine, manufacture or composition of 
matter".  And as in the US case, the Supreme Court confined itself to debating whether the words 
"manufacture" and "composition of matter", within the context of the Patent Act, are sufficiently 
broad to include higher life forms.  However, the Canadian Supreme Court argued that complex 
life forms did not fall under the category.  Justice Michael Bastarache stated “A complex life 
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form such as a mouse or a chimpanzee cannot easily be characterized as 'something made by the 
hands of man” (Kondro, 2002).  Therefore, patents did not seem to apply to a mouse. 
This situation frustrated scientists, especially since Canada had already approved patents 
for single-celled organisms, such as yeast and bacteria, and genetically modified crops.  It has 
also allowed patents for modified human genes and cell lines.  Harvard had earlier obtained a 
patent on the oncogene and related process claims from the Canadian Intellectual Property Office 
in 1993, but not on the mouse itself or its offspring with the oncogene.  The Commissioner of 
Patents upheld the negative decision in 1995, and the Trial Division of the Federal Court in 1998 
dismissed Harvard‟s appeal against this decision (Ching, 2003).  
However, scientists did not give up on this Canadian patent. In 2000, the Federal Court of 
Appeal overturned the trial judge and concluded that both the process and the mouse could be 
patented.  Ruling two-to-one in favor of the full patent, it said that nothing in Canada‟s 1869 
Patent Act outlawed patenting animals, although they asserted that it should not be extended to 
allow the patenting of human beings.  The Supreme Court ruling put the ball firmly in 
Parliament‟s court, and on December 5th, 2002, it ruled by five-to-four that a living mouse could 
not be patented, even if its genes are genetically modified.  It said the mouse fails to meet the 
definition of an invention (Ching, 2003).  
 
Other Animal Patents 
 Since the denial of the Oncomouse patent in Canada, eleven other countries including 
China, Russia, India, and Brazil have prohibited animal patents.  However, patenting animals in 
many other countries has become a widely accepted process. There have been 454 animal patents 
awarded since September 21, 2003, of which, 112 derive from federally funded research. Thirty 
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two patents currently involve human body parts in the animal, such as growing a prosthetic ear 
on the back of a mouse. Fifty-four percent of animal patents are strictly for disease models, and 
the other forty-six percent are for other purposes including bioreactors, drug screening, and 
general research.  There are twelve patents on dogs (American Anti-Vivisection Society, 2003). 
One genetically engineered goat transpharming the anticoagulant ATryn® (anti-thrombin to treat 
patients with its deficiency) became the first transpharmed product receiving FDA approval 
(U.S. Food and Drug Administration, 2009). 
Another milestone in transgenic animal patents happened on the 18
th
 of September in 
2008 when the US Food and Drug Administration (FDA) published new guidelines outlining 
how it proposes to streamline the patenting of animals and to regulate genetically engineered 
animals (Wadman, 2008).  These new guidelines should make it easier for US scientists to apply 
for patents for transgenic animals, while providing strong oversight of the entire process.  The 
patenting of animals has certainly come a long way since the trend-setting case of the famous 
Oncomouse. 
 
Negatives of Patenting Animals 
 One ethical issue some people have against the Patent and Trademark office is that it 
considered whether animals could be patented lawfully before it considered whether they should 
be patented ethically (Edwards, 2001).  However, the PTO argued that morality and ethics are 
not issues to be considered by the PTO and should instead be taken up through congress (Walter, 
1998).  Today, an animal can be patented as long as it fulfills the three requirements of utility, 
novelty, and non-obviousness.  
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 Many religions also disagree with the patenting of animals. Some do not believe that a 
human being should devalue the life of another animal by putting a price on it (Bioethics and 
Patent Law, 2006). Religious leaders also see problems with allowing companies to become 
wealthy through the production and sale of these living creatures.  These religious leaders also 
tend to less often perceive the benefit to human health that these animals can provide.  The 
advancement of this kind of technology may also grant a benefit to the patient taking the drug, 
but not to society in general.   
 Another problem with the patenting of these animals is that, seemingly, if a patent were 
obtained for a transgenic farm animal, those family farms without the economic advantage that 
transgenic animals bring would be run out of business. It would seem that larger corporations 
would be the only available buyers for this market. This, however, is not entirely true.  If a patent 
were not obtained protecting the general sale and use of the animal, the creators of these 
transgenic animals would license the animals to larger corporations that are capable of funding 
them, hindering medical research.  Only a small percentage of patented transgenic animals are 
farm animals, most are mice created for studying diseases and performing other scientific 
research, making the case for patentability stronger (Walter, 1998). 
 Then there is the ever lingering, ever controversial question of whether all of these 
transgenic animal models will lead down a slippery slope to the tampering of the human genome. 
The Patent and Trademark Office had already set forth specifications in the approval of other 
transgenic animal patents, and specifically excluding humans.  Many types of patented 
transgenic animals contain an inserted human gene, however, the PTO has not released a 
definition for how many genes it would take to create a banned human-animal chimera. 
Congress, which is eligible to use ethics as an argument, has not decided whether animals are 
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patentable.  They have established, however, that there are no current laws preventing it 
(Edwards, 2001). 
 
Positives of Patenting Animals 
 Without patents, the process of creating and selling transgenic animals would be a 
financial nightmare. The creators of the animal would need a huge amount of money for funding 
at the front and back ends of the project, so only large corporations could fund this research. 
Transgenic investments are incredibly risky, and there is no recipe for success, especially in the 
field of transgenics. Transgenic animals are particularly risky investments because there is no 
guarantee that the final product will be beneficial or function at all. One example would be the 
years scientists spent having trouble with xenotransplantation and hyper-acute rejection, with the 
problem still not solved.  For these reasons only the biggest companies in the business would be 
able to put serious money into these precarious projects.  As a case in point, DuPont, an 
industrial giant, invested $6 million in the Harvard Oncomouse (Blaug et al., 2004).  Without 
patents, there would be no revenue generated for the companies to benefit from their multi-
million dollar investments. 
 Another positive that comes out of the patenting of transgenic animals is that the revenue 
generated off of the patents can be reinvested in other biotechnological advances. This would 
enhance research and production of these companies, ultimately stimulating medical research 
and benefiting mankind through disease study and vaccine creation. Without this patent 
protection, there would be less monetary incentive to invest in, and therefore further, the 
biotechnological and biomedical industries.  So these patents are partly responsible for many of 
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the advancements we have made in the last decade or so against several diseases such as 
Parkinson‟s disease, Alzheimer‟s disease, cancer, and AIDS. 
 Another positive aspect of these patents is the visibility of new technologies. The more 
attention these innovations in biotechnology get, perhaps the more interest it stimulates among 
the public and the scientific community.  More interest means a better opportunity for 
improvements on patents, ultimately leading to further advancements and breakthroughs in the 
world of medicine.  We, the authors of this IQP, along with millions of people around the world, 
believe that the benefit this transgenic technology can provide to society far outweighs the risks 
it may bear.  These risks, however, should not be dismissed, but carefully analyzed, studied and 
finally incorporated into the patent law and serve as guiding principles for institutional Animal 
Care and Use Committees (IACUC) to tightly oversee the entire process to help ensure that any 
animal suffering is minimized.   
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PROJECT CONCLUSIONS 
 
 
Based on the research performed in this project, the authors believe that all five major 
classes of transgenic animals (disease models, transpharmers, xenotransplanters, food sources, 
and biological models) should be continued, while minimizing those types of experiments that 
have no strong medical benefits to society (like ANDi that produced Green Florescent Protein). 
In all cases, every effort should be made to minimize any animal suffering if it occurs.  The 
authors also believe that transgenic fish should be approved by the FDA to help fight world 
hunger, but agree that any “Super mammals” who‟s health may be compromised through 
transgenesis (such as Superpig) should not be allowed.  In this case, the animal‟s suffering far 
outweighs any benefits to society. In all cases, strong animal committee and legislative 
oversights should be followed to help ensure that any experiments gone wrong lead to immediate 
animal euthanasia to prevent as much of the animal‟s suffering as possible. 
Both authors agree that the patenting of transgenic animals, although controversial, is 
extremely beneficial not only to the companies that produce them, but for the entire medical 
community.  However, the authors do agree with the limitations on animal patents by the United 
States Patent Office (PTO) and the European Patent Office (EPO) to make unlawful the 
tampering of the human genome. Overall, both authors of this paper believe that many transgenic 
applications are beneficial to society, and should be continued. 
 
